What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Cells

Daniel M. Berney¹  Stefania Croci²  Martina Bonacini²  Carolina Castro Ruiz³  Jatin Gandhi⁴  Alessandra Soriano⁵  Cristina Magi-Galluzzi⁶  Sofia Cañete-Portillo⁶  Dario De Biase⁷  Alcides Chaux⁸  Giuseppe Carrieri⁹  Luigi Cormio⁹  Daniel Athanazio^1,10  Beatrice Melli^1,11  Guido Giordano^1,12  Matteo Landriscina^1,12  Antonio De Leo^1,13  Stefano Ascani^1,14  Moira Ragazzi^1,15  Giacomo Santandrea^1,15  Alberto Cavazza^1,15  Maria Paola Bonasoni^1,15  Alessandro Tafuni^1,15  Eleonora Zanetti^1,15  Alessandra Bisagni^1,15  Magda Zanelli^1,15  Andrea Palicelli^1,15  Francesca Sanguedolce^1,16  Maurizio Zizzo^1,17 

[1] Barts Cancer Institute, Queen Mary University of London, London EC1M 5PZ, UK;Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy;Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy;Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA;Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA;Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA;Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy;Department of Scientific Research, School of Postgraduate Studies Norte University, Asunción 1614, Paraguay;Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy;Federal University of Bahia, Salvador 40110-060, BA, Brazil;Fertility Center, Department of Obstetrics and Gynecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy;Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy;Molecular Diagnostic Unit, Azienda USL Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy;Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy;Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy;Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy;Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy;

关键词: PD-L1;    prostate;    cancer;    adenocarcinoma;    immunohistochemistry;    target-therapy;   

DOI  :  10.3390/cells10113166

来源: DOAJ

【 摘 要 】

Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.

【 授权许可】

Unknown